Sign in

Abstract

Structured AbstractO_ST_ABSINTRODUCTIONC_ST_ABSPlasma biomarkers for Alzheimer disease (AD) hold promise for disease diagnosis and prediction, yet their genetic underpinnings remain underexplored. METHODSWe measured plasma amyloid beta 40 (A{beta}40), A{beta}42, A{beta}42/A{beta}40, total tau (t-tau), phosphorylated tau 181 (p-tau181), A{beta}42/t-tau, A{beta}42/p-tau181, neurofilament light chain, and glial fibrillary acidic protein in the Midwestern Amish. Pedigree-based heritability [Formula] was estimated from multigenerational pedigrees, and SNP-based heritability [Formula] was derived from single nucleotide polymorphisms (SNPs). RESULTSAmong all Amish individuals, additive genetic effects [Formula] explained 11.1% to 36.6% of biomarker variances. [Formula] estimates were consistently lower, ranging from 6.7% to 28.7%. The heritability of these biomarkers in subgroups of cognitively normal individuals and APOE {varepsilon}4 non-carriers yielded similar results. DISCUSSIONPlasma biomarkers such as amyloid {beta}, t-tau, and p-tau181 are moderately heritable in the Amish, underscoring the impact of genetic determinants of plasma biomarkers associated with AD.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.